Iovance Biotherapeutics, Inc.
http://www.iovance.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Iovance Biotherapeutics, Inc.
Iovance Sparks More Optimism About Lifileucel’s Commercial Potential With New Analysis
The company is presenting an updated Phase II analysis at SITC as it prepares to complete its rolling BLA submission and readies its commercial launch.
Academic Study Boosts Belief In TIL Therapies, Including Iovance’s Lifileucel
A new academic study presented at ESMO has provided the first Phase III data for tumor-infiltrating lymphocytes as a potential new therapeutic class, while industry leader Iovance looks set to have early-stage data for its TIL accepted by the US FDA.
Keeping Track: US FDA Clears New Uses For Incyte’s Pemazyre, AbbVie’s Imbruvica; Minerva Seeks First Negative Symptoms Claim In Schizophrenia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Adaptimmune Starts Planning TCR Commercialization For An Ultra Rare Patient Population
CEO Adrian Rawcliffe talked with Scrip about filing and early commercial plans for afami-cel in synovial carcinoma if it is approved by the FDA.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Genesis Biopharma
- Lion Biotechnologies, Inc. (LBIO)